Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
As a challenging first half nears a close, biopharma uncertainty persists
Yesterday
Financing
Pharma
Astellas licenses Claudin18.2 ADC from China’s Evopoint Biosciences
2 days ago
China
Post-Hoc Live: Is biotech sentiment really as bad as it seems?
3 days ago
Financing
Editor's note
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined
4 days ago
Lilly to buy non-opioid pain biotech SiteOne for up to $1B
4 days ago
Pharma
Biogen taps City Therapeutics in RNAi deal worth up to $1B
4 days ago
Startups
Pharma
Blackstone's GRIN inks epilepsy licensing deal with Angelini, closes $140M Series D
4 days ago
Pharma
TCG's R&D venture team makes a T cell engager deal with Shanghai biotech
4 days ago
Startups
China
Updated: Hinge Health jumped 18% on its first day as the digital health IPO market reawakens
Last week
Financing
Health Tech
Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen
Last week
Pharma
BioNTech invests £1B in growing UK footprint under expanded pact with government
Last week
R&D
Genentech expands deal with molecular glue biotech Orionis for $105M upfront
Last week
R&D
Altos Labs buys anti-aging startup Dorian Therapeutics
Last week
Startups
Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio
Last week
China
Pharma
Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in funds
Last week
Startups
Cell/Gene Tx
Why Regeneron is buying 23andMe
Last week
Regeneron plans to buy 23andMe for $256M
Last week
Pharma
BioMarin makes Phase 3 buy, paying $270M for rare disease outfit Inozyme
3 weeks ago
Pharma
Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B
3 weeks ago
Startups
Cell/Gene Tx
Exclusive: Datavant to acquire real-world data specialist Aetion, doubling life sciences team
3 weeks ago
AI
AbbVie doubles down on siRNA with $335M upfront bet on ADARx
3 weeks ago
Startups
Pharma
GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope
3 weeks ago
Pharma
Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B
3 weeks ago
Pharma
Cedars-Sinai partners with Redesign Health to build health tech startups
4 weeks ago
Health Tech
1
2
3
4
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit